Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells

Journal of Biological Chemistry

Volumn 278, Issue 22, 2003, Pages 19619-19626

  Rahman, Mujib M ^a   Miyamoto, Hiroshi ^a   Takatera, Hiroshi ^a   Yeh, Shuyuan ^a   Altuwaijri, Saleh ^a   Chang, Chawnshang ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; MUTAGENESIS; OLIGOMERS; TUMORS;

ANTIANDROGENS;

HORMONES;

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR COREGULATOR ARA70; ANTIANDROGEN; UNCLASSIFIED DRUG; DNA; NCOA4 PROTEIN, HUMAN; ONCOPROTEIN; PRIMER DNA; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; TWO HYBRID SYSTEM; YEAST; ANIMAL; CELL CULTURE; DOMINANT GENE; DRUG POTENTIATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RNA INTERFERENCE;

ANIMALIA;

ANDROGEN ANTAGONISTS; ANIMALS; BASE SEQUENCE; DNA PRIMERS; DNA, NEOPLASM; GENE SILENCING; GENES, DOMINANT; HUMANS; MALE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0038165446     PISSN: 00219258     EISSN: None     Source Type: Journal    
DOI: 10.1074/jbc.M210941200     Document Type: Article

References (39)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. (2001) CA Cancer J. Clin. 51, 15-36
2. Huggins, C., Stevens, R., and Hodges, C. V. (1941) Arch. Surg. 43, 209-233
3. Westin, P., Stattin, P., Damber, J.-E., and Bergh, A. (1995) Am. J. Pathol. 146, 1368-1375
4. Dennis, L. J., and Griffiths, K. (2000) Semin. Surg. Oncol. 18, 52-74
5. Labrie, F., Belanger, A., Dupont, A., Luu-The, V., Simard, J., and Labrie, C. (1993) Clin. Invest. Med. 16, 475-492
6. Goktas, S., and Crawford, E. D. (1999) Semin. Oncol. 26, 162-173
7. Schellhammer, P. F. (1996) Urology 47, 622-628
8. Prostate Cancer Trialist's Collaborative Group (2000) Lancet 355, 1491-1498
9. Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parezyk, K., and Klocker, H. (1999) Br. J. Cancer 81, 242-251
10. Miyamoto, H., Yeh, S., Wilding, G., and Chang, C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7379-7384
11. Yeh, S., Miyamoto, H., and Chang, C. (1999) Lancet 349, 852-853
12. Kelly, W. K. (1998) Eur. Urol. 34, Suppl. 3, 18-23
13. Grossmann, M. E., Huang, H., and Tindall, D. J. (2001) J. Natl. Cancer Inst. 93, 1687-1697
14. Feldman, B. J., and Feldman, D. (2001) Nat. Rev. Cancer 1, 34-45
15. Yeh, S., and Chang, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5517-5521
16. Yeh, S., Kang, H.-Y., Miyamoto, H., Nishimura, K., Chang, H.-C., Ting, H.-J., Rahman, M., Lin H.-K., Fujimoto, N., Hu, Y.-C., Mizokami, A., Huang, K. E., and Chang, C. (1999) Endocrine 11, 195-202
17. Kang, H.-Y., Yeh, S., Fujimoto, N., and Chang, C (1999) J. Biol. Chem. 274, 8570-8576
18. Yeh, S., Chang, H.-C., Miyamoto, H., Takatera, H., Rahman, M., Kang H.-Y., Thin, T. H., Lin H.-K., and Chang, C (1999) Keio J. Med. 48, 87-92
19. Fujimoto, N., Yeh, S., Kang, H.-Y., Inui, S., Chang, H.-C., Mizokami, A., and Chang, C. (1999) J. Biol. Chem. 274, 8316-8321
20. Miyamoto, H., Yeh, S., Lardy, H., Messing, E., and Chang, C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11083-11088
21. Miyamoto, H., and Chang, C. (2000) Int. J. Urol. 7, 32-34
22. Zhou, Z.-X., He, B., Hall, S. H., Wilson, E. M., and French, F. S. (2002) Mol. Endocrinol. 16, 287-300
23. Gao, T., Brantley, K., Bolu, E., and McPhaul, M. J. (1999) Mol. Endocrinol. 13, 1645-1656
24. Agoulnik, I., Stenoien, D., Mancini, M. A., and Weigel, N. (2000) Keystone Steroid Symposium, Steamboat Springs, Colorado, March 25-31, 2000, p. 116, Abstr. 202, Bristol-Myers Squibb Pharmaceuticals Research Institute and Director's Sponsor Fund, Steamboat Springs, CO
25. Han, G., Foster, B. A., Mistry, S., Buchanan, G., Harris, J. M., Tilley, W. D., and Greenberg, N. M. (2001) J. Biol. Chem. 276, 11204-11213
26. Truica, C. I., Byers, S., and Gelmann, E. P. (2000) Cancer Res. 60, 4709-4713
27. Craft, N., Shostak, Y., Carey, M., and Sawyears, C. (1999) Nat. Med. 5, 280-285
28. Yeh, S., Lin, H.-K., Kang, H.-Y., Thin, T. H., Lin, M.-F., and Chang, C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5458-5463
29. Sikorski, R. S., and Boeke, J. D. (1991) Method Enzymol. 194, 302-318
30. Sui, G., Soohoo, C., Affar, E. B., Gay, F., Shi, Y., Forrester, W. C., and Shi, Y. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 5515-5520
31. Miyamoto, H., Rahman, M., Takatera, H., Kang, H.-Y., Yeh, S., Chang, H.-C., Nishimura, K., Fujimoto, N., and Chang, C. (2002) J. Biol. Chem. 277, 4609-4617
32. Palmberg, C., Koivisto, P., Visakorpi, T., and Tammela, T. L. (1999) Eur. Urol. 36, 191-196
33. Kelly, W. K., Scher, H. I., Mazumdar, M., Vlamis, V., Schwartz, M., and Fossa, S. D. (1993) J. Clin. Oncol. 11, 607-615
34. Gopalbhai, K., Jansen, G., Beauregard, G., Whiteway, M., Dumas, F., Wu, C., and Meloche, S. (2003) J. Biol. Chem. 278, 8118-8125
35. Hecker, A., Testeniere, O., Marin, F., and Luquet, G. (2003) FEBS Lett. 535, 49-54
36. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. (1999) Cancer Res. 59, 2511-2515
37. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. (1995) N. Engl. J. Med. 332, 1393-1398
38. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. (1993) Mol. Endocrinol. 7, 1541-1550
39. Haapala, K., Hyytinen, E. R., Roiha, M., Laurila, M., Rantala, I., Helin, H. J., and Koivisto, P. (2001) Lab. Invest. 81, 1647-1651